These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11982739)

  • 1. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy.
    Dalgard O; Bjøro K; Hellum K; Myrvang B; Bjøro T; Haug E; Bell H
    J Intern Med; 2002 May; 251(5):400-6. PubMed ID: 11982739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.
    Hsieh MC; Yu ML; Chuang WL; Shin SJ; Dai CY; Chen SC; Lin ZY; Hsieh MY; Liu JF; Wang LY; Chang WY
    Eur J Endocrinol; 2000 May; 142(5):431-7. PubMed ID: 10802518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
    Bini EJ; Mehandru S
    Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
    Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
    Nadeem A; Aslam M; Khan DA; Hussain T; Khan SA
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):86-9. PubMed ID: 19208310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
    Bjøro K; Bell H; Hellum KB; Skaug K; Raknerud N; Sandvei P; Døskeland B; Maeland A; Lund-Tønnesen S; Myrvang B
    Scand J Gastroenterol; 2002 Feb; 37(2):226-32. PubMed ID: 11843062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
    Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
    Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy.
    Andrade LJ; Atta AM; Atta ML; Mangabeira CN; Paraná R
    Braz J Infect Dis; 2011; 15(4):377-81. PubMed ID: 21861010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-induced thyroid dysfunction in chronic hepatitis C.
    Jamil KM; Leedman PJ; Kontorinis N; Tarquinio L; Nazareth S; McInerney M; Connelly C; Flexman J; Burke V; Metcalf C; Cheng W
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1017-23. PubMed ID: 19054259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy.
    Deutsch M; Dourakis S; Manesis EK; Gioustozi A; Hess G; Horsch A; Hadziyannis S
    Hepatology; 1997 Jul; 26(1):206-10. PubMed ID: 9214471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
    J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C.
    Doi F; Kakizaki S; Takagi H; Murakami M; Sohara N; Otsuka T; Abe T; Mori M
    Liver Int; 2005 Apr; 25(2):242-6. PubMed ID: 15780045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
    Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
    Teng ZL; Gong WJ; Zhang SQ; Sun YX; Ma XH
    Zhonghua Gan Zang Bing Za Zhi; 2013 Feb; 21(2):101-4. PubMed ID: 23663880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection.
    Masood N; Ghori R; Memon A; Memon S; Memon KI; Memon I; Jaffri M; Baloch GH
    J Coll Physicians Surg Pak; 2008 Jun; 18(6):347-51. PubMed ID: 18760045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
    Obołończyk Ł; Siekierska-Hellmann M; Wiśniewski P; Lewczuk A; Berendt-Obołończyk M; Lakomy A; Michalska Z; Radowska D; Moszkowska G; Bianek-Bodzak A; Sworczak K
    Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):842-849. PubMed ID: 29039351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.